Sulphonylurea efficacy and end-organ outcomes in the management of HNF4A-MODY.

ABSTRACT:

Aims

Sulphonylurea agents are typically used to treat HNF4A-MODY based on the pharmacogenetic aetiology of the condition, although limited evidence exists in the literature for this practice. The aims of this study were to determine the efficacy of sulphonylurea drugs during follow-up, to explore the role of adjunctive therapies in this cohort and to describe micro- and macrovascular complications over longitudinal follow-up.

Methods

Forty-two individuals with an HNF4A mutation were phenotyped in detail, including an oral glucose tolerance test to establish insulin secretory capacity. Subsequent markers, including oral hypoglycaemic usage, end-organ complications, weight, cardiovascular co-morbidity and biochemistry including HbA_1c and urinary albumin, were record

SUBMITTER: Crowley MT 

PROVIDER: S-EPMC12628745 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature